The dosage of lenalidomide needs to be adjusted under doctor’s supervision after complete remission of multiple myeloma. Lenalidomide can inhibit the secretion of vascular endothelial growth factor by myeloma cells and bone marrow stromal cells. Currently, lenalidomide is a more effective drug in the treatment of multiple myeloma, and it usually requires lifelong medication to prolong the patient’s life. Patients with multiple myeloma take lenalidomide for 28 days per cycle, with a daily dosage of 25mg on days 1-21. the first 4 cycles can be taken with dexamethasone. Lenalidomide is a prescription drug and needs to be adjusted according to the patient’s condition and age. It is recommended to use the drug under the guidance of the doctor, not blindly self-medication. To avoid adverse reactions.